Selecta Biosciences appoints Peter Keller vice-president and alliance manager
This article was originally published in Scrip
Selecta Biosciences, a biopharmaceutical company developing targeted vaccines and immunotherapies, has appointed Peter Keller vice-president of business development and alliance manager. Prior to joining Selecta, Mr Keller led the integration process for Abbott Laboratories' R&D and manufacturing facilities. He will report to Dr Werner Cautreels, Selecta's CEO.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.